Using Dose Titration to Resolve Vomiting on Zepbound (tirzepatide)

What the label actually controls

Zepbound is a once-weekly subcutaneous injection of tirzepatide, a dual GIP and GLP-1 receptor agonist approved to reduce excess body weight in adults with obesity or overweight plus a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity [1].

The labeled schedule has two stages. Treatment starts at 2.5 mg injected once weekly for 4 weeks; that dose is for treatment initiation and is not approved as a maintenance dose [1]. After 4 weeks the dose goes to 5 mg once weekly, and any further increase is made in 2.5 mg increments after at least 4 weeks on the current dose, to a maximum of 15 mg weekly [1]. Maintenance doses are 5, 10 or 15 mg for weight reduction and 10 or 15 mg for sleep apnea [1].

Two label sentences matter most when vomiting appears. The label states that this escalation schedule is followed to reduce the risk of gastrointestinal adverse reactions [1]. And for maintenance: 'Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage' [1].

How often vomiting happens, by dose

Those rates come from a pool of two placebo-controlled weight-management trials in adults with obesity or overweight, with or without type 2 diabetes, running up to 72 weeks: 958 people on placebo and 630, 948 and 941 people on 5, 10 and 15 mg [1]. Vomiting occurred in 2% of people on placebo and 8%, 11% and 13% on Zepbound 5, 10 and 15 mg, respectively [1]. Nausea occurred in 8% of people on placebo and 25%, 29% and 28% on the three doses, respectively [1]. Diarrhea occurred in 8% of people on placebo and 19%, 21% and 23% on the three doses, and constipation in 5% versus 17%, 14% and 11% [1]. Any gastrointestinal adverse reaction was reported by 56% of people on every Zepbound dose, against 30% on placebo [1].

Severe gastrointestinal adverse reactions were reported in 1.7% of people on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, against 1% on placebo [1]. Treatment was stopped for a gastrointestinal adverse reaction by 1.9%, 3.3% and 4.3% of people on 5, 10 and 15 mg, against 0.5% on placebo, and the label says the majority of those who stopped for any adverse reaction did so in the first few months, due to gastrointestinal reactions [1].

On timing, the label's statement is broad: the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1].

Holding a dose longer before the next step

For increases beyond 5 mg, the label treats the interval as a floor rather than a deadline: the dose 'may be increased in 2.5 mg increments, after at least 4 weeks on the current dose' [1]. A schedule that spends longer than 4 weeks at 5 mg or above before taking the next 2.5 mg step therefore still fits that part of the escalation rule [1].

The first step is different. The label specifies 2.5 mg once weekly for 4 weeks and then 5 mg, and it does not describe an extended stay at 2.5 mg as part of the labeled schedule [1]. The label does not report whether a longer stay at any dose lowers vomiting.

Stepping back to a lower maintenance dose

The label's step-down instruction is written for maintenance dosages: if a maintenance dosage is not tolerated, consider a lower maintenance dosage [1]. For weight reduction the labeled maintenance options are 5, 10 or 15 mg weekly, so 5 mg is the named maintenance option below 10 mg [1]. For sleep apnea the options are 10 or 15 mg [1].

The 2.5 mg dose is a special case. The label states it is for treatment initiation and is not approved as a maintenance dosage [1].

What about a break between doses

The label's only timing rule for a gap is the missed-dose instruction: for a missed dose, the Zepbound label allows administration within 4 days (96 hours). After that, it says to skip the missed dose and resume on the regular day. The weekly day can be changed if two doses are at least 3 days (72 hours) apart [1]. Tirzepatide has a half-life of about 5 days and reaches steady state after 4 weeks of weekly dosing [1].

In SURMOUNT-4, among the 670 adults randomized after 36 weeks of open-label tirzepatide, mean weight loss at that point was 20.9%; they were then randomized to continue tirzepatide or switch to placebo for 52 weeks, and weight changed by -5.5% with continued treatment versus +14.0% after the switch [2]. That was a full withdrawal rather than a short pause.

Splitting the weekly dose

Zepbound is labeled as one injection once weekly, in a vial, a prefilled single-dose pen or a single-patient-use KwikPen, and the label says people should be trained on the specific presentation they receive [1]. Dividing the week into two smaller injections is not part of the labeled regimen [1].

When vomiting is more than a titration problem

The label warns that gastrointestinal reactions can lead to dehydration and acute kidney injury, in some cases requiring hemodialysis, with the majority of reported events in people who had nausea, vomiting or diarrhea, and says renal function should be monitored in patients reporting reactions that could cause volume depletion, especially during initiation and dose escalation [1].

Acute pancreatitis has been observed with GLP-1 receptor agonists and with Zepbound. The label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says Zepbound should be discontinued if pancreatitis is suspected [1].

Gallbladder disease is also on the label: in the pooled weight trials, cholelithiasis was reported in 1.1% of Zepbound-treated patients versus 1% on placebo, and cholecystitis in 0.7% versus 0.2% [1]. Zepbound is not recommended in people with severe gastroparesis [1].